On July 4, 2025, a new ancillary study to the SHIVA cohort was launched at Bordeaux University Hospital (CHU de Bordeaux): the SHIVA-CogNeurophys study, sponsored by the CHU.
This study aims to better understand cognitive disorders (particularly memory and attention impairments) associated with cerebral small vessel disease (CSVD) — a common brain condition that can lead to strokes and progressive cognitive decline.
🔬 An innovative exploratory study
SHIVA-CogNeurophys seeks to explore, through non-invasive approaches, how the brain functions during simple cognitive tasks and how these functions are altered in CSVD.
Participants — all from the SHIVA cohort at Bordeaux University Hospital — will undergo:🤝 Voluntary and supervised participation
- Electroencephalogram (EEG) recordings of brain activity,
- Mild brain stimulation using transcranial alternating current stimulation (tACS),
- And personalized cognitive training at home through computer-based exercises.
The study will last 6 months, including 5 scheduled hospital visits. It will involve 80 voluntary patients enrolled in the SHIVA cohort at CHU de Bordeaux, subject to eligibility criteria. Travel expenses are covered.
While this research has no immediate therapeutic purpose, it could ultimately pave the way for new strategies to manage cognitive disorders in this disease, which remains little known to the general public.
Participation is entirely voluntary and conducted under a strictly supervised protocol, approved by an Ethics Committee for the Protection of Individuals.
All personal data are handled with strict confidentiality, in compliance with the General Data Protection Regulation (GDPR).
📍 Sponsor: CHU de Bordeaux – 12 Rue Dubernat, 33404 Talence Cedex
👨⚕️ Principal Investigator: Prof. Igor Sibon
👨⚕️ Co-Principal Investigator: Dr. Jean-Sébastien Liégey
